SCHEMBL5606988

SCHEMBL5606988

NC(Cc1ccc(CNC(=O)c2ccccc2Cl)cc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.54
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
PTGS1 P23219 1/20 0.54
XIAP P98170 1/20 0.54
APEX1 P27695 1/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
SMO Q99835 1/20 0.50
HPGD P15428 4/20 0.49
LMNA P02545 3/20 0.49
GFER P55789 1/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 3/20 0.48
POLB P06746 1/20 0.48
HSP90AA1 P07900 1/20 0.48
GAA P10253 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5606984 1.00 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL5607148 0.84 SMO (0.70) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL5078480 0.84 SMO (0.70) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL5607190 0.84 MAPK1 (0.59) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL5607183 0.84 MAPK1 (0.59) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL5860823 0.83 NPC1 (0.71) APEX1NPC1RAB9AHPGDLMNA
SCHEMBL5607088 0.82 SLC7A5 (0.62) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL5082554 0.82 SLC7A5 (0.62) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL5608115 0.81 HPGD (0.71) RAB9AHPGDLMNAKMT2AALDH1A1
SCHEMBL5608111 0.81 HPGD (0.71) RAB9AHPGDLMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP SLC7A5 2674/4885ALPI 301/4885PKM 2260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.